Business · 21/08/2025
FDA Classifies Cancer Predisposition Risk Assessment System into Class II
The FDA has classified the Cancer Predisposition Risk Assessment System into Class II, a special control classification, to ensure the device's safety and effectiveness while reducing regulatory burdens and enhancing patient access to innovative devices.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →